Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

被引:9
|
作者
Ren, Yifan [1 ]
Song, Jialong [1 ]
Li, Xinyi [1 ]
Luo, Na [1 ]
机构
[1] Nankai Univ, Sch Med, Dept Histol, Tianjin 300071, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer therapy; metastatic triple-negative breast cancer; anticancer drugs; immunotherapy; immune checkpoint blockade therapy; PD-1; PD-L1; clinical trails; CHECKPOINT BLOCKADE; ANTITUMOR IMMUNITY; 1ST-LINE TREATMENT; PLUS CHEMOTHERAPY; DOUBLE-BLIND; OPEN-LABEL; T-CELLS; ATEZOLIZUMAB; PEMBROLIZUMAB; THERAPY;
D O I
10.3390/ijms23168878
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combination of PD-1/PD-L1 inhibitors with other therapies is a noteworthy treatment strategy. Immunotherapy in combination with chemotherapy or small-molecule inhibitors still faces many challenges. Additionally, there are some new immunotherapy targets in development. We aimed to further evaluate the effectiveness and usefulness of immunotherapy for treating mTNBC and to propose new immunotherapy strategies. This review explains the rationale and results of existing clinical trials evaluating PD-1/PD-L1 inhibitors alone or in combination for the treatment of mTNBC. For patients with aggressive tumors and poor health, PD-1/PD-L1 inhibitors, either alone or in combination with other modalities, have proven to be effective. However, more research is needed to explore more effective immunotherapy regimens that will lead to new breakthroughs in the treatment of mTNBC.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking
    He, Rui
    Yuan, Xing
    Chen, Zeran
    Zheng, Yongfeng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113
  • [2] Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
    Kumar, Sunny
    Chatterjee, Mouli
    Ghosh, Pratyasha
    Ganguly, Kirat K.
    Basu, Malini
    Ghosh, Mrinal K.
    GENES & DISEASES, 2023, 10 (04) : 1318 - 1350
  • [3] PD-1/PD-L1 inhibitor-based immunotherapy in locally advanced or metastatic triple-negative breast cancer: A meta-analysis
    Chen, Yonghui
    Shi, Liji
    Yin, Weihua
    Xia, Hongmei
    Lin, Canling
    ONCOLOGY LETTERS, 2025, 29 (01)
  • [4] Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy
    Chen, Fei
    Chen, Naifei
    Gao, Yangyang
    Jia, Lin
    Lyu, Zheng
    Cui, Jiuwei
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [5] Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
    Yang, Tinglin
    Li, Wenhui
    Huang, Tao
    Zhou, Jun
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (03):
  • [6] A meta-analysis of application of PD-1/PD-L1 inhibitor-based immunotherapy in unresectable locally advanced triple-negative breast cancer
    Zhang, Wei
    He, Yujing
    Tang, Yuning
    Dai, Wei
    Si, Yuexiu
    Mao, Feiyan
    Xu, Jiaxuan
    Yu, Chiyuan
    Sun, Xing
    IMMUNOTHERAPY, 2023, 15 (13) : 1073 - 1088
  • [7] Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Hongshu Li
    Ying Chang
    Tiefeng Jin
    Meihua Zhang
    Cancer Cell International, 25 (1)
  • [8] A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer
    Wang, Chaoyang
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [9] Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review
    Tavares, Dione Fernandes
    Ribeiro, Victoria Chaves
    Vieira Andrade, Marco Antonio
    Cardoso-Junior, Laercio Moreira
    Gomes Teixeira, Thiago Rhangel
    Varrone, Gabriela Ramos
    Britto, Renata Lopes
    ONCOLOGY REVIEWS, 2021, 15 (02)
  • [10] PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
    Yu, Yinan
    Jin, Xueying
    Zhu, Xiaoling
    Xu, Yan
    Si, Wei
    Zhao, Jianguo
    FRONTIERS IN IMMUNOLOGY, 2023, 14